Trade Mark Journal No.2026/040 2 October 2026
UK00004446891 17 September 2026 (5)
EMLOQMO
International priority date claimed: 26 March 2026
(United States of America)
(99727481)
- Class 5
- Pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke.
Amgen Inc.
Representative: Stevens Hewlett & Perkins